The major pharmaceutical markets are the US, Europe (where the UK, Spain, France, Italy and Germany are the major players), Japan and the rest of the world. As I explain in the section on industry, the US comprises about 40–50% of the market, Europe with 20%, Japan with 10% and the rest of the world at 20%. As the US share drops because of the recession and increasing competition and health care reform, the emerging markets like China, India and others are taking up the slack. Europe, nevertheless remains an important market. They have a complex regulatory environment and tough pricing policies. Europe has been ahead of the curve in recognizing the perfect storm afflicting antibiotics. Whether they will actually act in accordance with their published analyses and resultant recommendations for dealing with the storm remains to be seen.